New asthma treatment
Pharmacy Magazine,
17 Apr 2019
1 Min
Clinical
New asthma treatment
Pharmacy Magazine,
17 Apr 20191 Min
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.
Bookmark
Record learning outcomes
The CHMP has approved dupilumab (Dupixent) as add-on maintenance treatment for some patients 12 years and older with severe asthma.
Eligible patients have inflammation characterised by raised blood eosinophils, increased fractional exhaled nitric oxide, or both, and are inadequately controlled with high-dose inhaled corticosteroid plus another maintenance treatment.
Dupilumab inhibits overactive signalling by both interleukin-4 and interleukin-13.
Copy Link
Record my learning outcomes
Save for later
Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.
In Clinical
Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.